Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Renal-Cell Cancer
SBRT plus Immunotherapy in Metastatic Renal-Cell Carcinoma Warrants Further Study
By
Phoebe Starr
Renal-Cell Cancer
Web Exclusives
San Francisco, CA—Although there is a biological rationale that supports the “abscopal” effects of radiation therapy plus checkpoint immunotherapy in fighting cancer, this combination showed mixed results and no robust effects in patients with metastatic renal-cell carcinoma (RCC), according to results of 2 preliminary studies presented at the 2020 Genitourinary Cancers Symposium.
Read Article
Sitravatinib, Novel TKI, plus Nivolumab Elicits Good Responses in Renal-Cell Carcinoma
By
Phoebe Starr
Renal-Cell Cancer
June 2020, Vol 11, No 3
San Francisco, CA—The combination of nivolumab (Opdivo) plus the investigational drug sitravatinib improved progression-free survival (PFS) in patients with pretreated metastatic clear-cell renal-cell carcinoma (RCC) and the historical disease control rates compared with nivolumab alone, according to the results of a phase 1/2 clinical trial reported at the 2020 Genitourinary Cancers Symposium.
Read Article
First-in-Class Oral MK-6482 Shows Exciting Results in Clear-Cell Renal-Cell Carcinoma
By
Phoebe Starr
Renal-Cell Cancer
June 2020, Vol 11, No 3
San Francisco, CA—Treatment with the novel agent MK-6482 led to promising results in a phase 1/2 clinical trial of patients with metastatic clear-cell renal-cell carcinoma (RCC). In heavily pretreated patients, the objective response rate (ORR) with single-agent MK-6482 was 24%, and a response was consistently seen across patients with favorable-, intermediate-, and poor-risk disease. These results were greeted with optimism at the 2020 Genitourinary Cancers Symposium.
Read Article
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma